LONA · XBRL financial data

LeonaBio financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LONA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	13,286	42,794	61,464	93,790	70,682	17,500
General and administrative	6,709	21,228	32,552	33,304	26,093	16,678
Operating income (loss)	(19,995)	(64,022)	(104,016)	(125,466)	(100,902)	(102,266)
Interest expense	367	3	—	—	—	—
Other income (expense)	(1,281)	334	3,216	7,637	3,962	1,236
Income tax expense (benefit)	—	—	—	—	—	0
Net income (loss)	(19,955)	(54,853)	(95,639)	(117,672)	(96,940)	(105,609)
Earnings per share, basic‡ USD per share	—	(14.90)	(25.30)	(30.90)	(25.20)	(24.70)
Earnings per share, diluted‡ USD per share	—	(14.90)	(25.30)	(30.90)	(25.20)	(24.70)
Weighted average shares, basic‡ thousands of shares	—	3,692	3,773	3,802	3,848	4,276
Weighted average shares, diluted‡ thousands of shares	—	3,692	3,773	3,802	3,848	4,276

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.

Fiscal years (LONA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	60,625	110,537	95,966	90,584	48,438	69,276
Short-term investments	124,057	143,222	104,378	56,835	2,837	19,055
Prepaid and other current assets	6,355	4,704	5,962	5,682	3,566	1,127
Total current assets	192,337	260,799	207,533	154,729	54,841	89,458
Property and equipment, net	2,649	3,757	4,053	3,388	2,444	1,472
Right-of-use asset	936	1,460	1,263	1,049	808	535
Total assets	279,563	332,008	258,153	160,245	58,779	92,151
Accounts payable	1,158	567	2,501	129	319	4,587
Accrued liabilities	3,123	8,437	8,604	18,343	12,402	4,963
Total current liabilities	4,405	9,292	21,431	28,840	13,135	47,503
Lease liability, non-current	876	1,632	1,585	1,217	803	338
Total liabilities	5,281	10,924	23,016	30,057	13,938	64,361
Accumulated deficit	(41,042)	(95,895)	(191,534)	(309,206)	(406,146)	(511,755)
Total stockholders' equity	274,282	321,084	235,137	130,188	44,841	27,790
Total liabilities and equity	279,563	332,008	258,153	160,245	58,779	92,151
Common shares outstanding (cover page)‡ thousands of shares	3,712	3,762	3,794	3,833	3,904	9,336

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.

Fiscal years (LONA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(19,955)	(54,853)	(95,639)	(117,672)	(96,940)	(105,609)
Stock-based compensation	633	4,623	10,606	10,623	11,049	6,102
Net cash from operating activities	(24,113)	(43,098)	(72,469)	(100,753)	(97,170)	(45,729)
Purchases of property and equipment	2,320	1,573	1,141	304	33	—
Net cash from investing activities	(210,068)	(4,079)	57,664	95,089	54,830	(15,894)
Proceeds from issuing common stock	—	—	—	—	—	89,991
Net cash from financing activities	292,750	97,089	654	493	194	82,461
Net change in cash	58,569	49,912	(14,151)	(5,171)	(42,146)	20,838

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Brainstorm Cell Therapeutics	22	not reported	(895)	11.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.